{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00027786", "CSN": null, "TRF": "ORD_1587798_01", "MRN": "30431324", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1291792", "clinicalId": "1293142", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1587798_01", "SampleName": "US1517083.01", "Version": "0", "Sample": {"FM_Id": "ORD_1587798_01", "SampleId": "US1517083.01", "BlockId": "S112-65411H", "TRFNumber": "ORD_1587798_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2023_03_15", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}]}, "TumorPurity": "35", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10072", "MRN": "30431324", "FullName": "\u9673\u7d20\u840d", "FirstName": "Su Ping", "LastName": "Chen", "SubmittedDiagnosis": "Ovary clear cell carcinoma", "Gender": "Female", "DOB": "1971_02_06", "OrderingMD": "\u9673\u6021\u4ec1", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u582f", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Ovary", "CollDate": "2023_02_06", "ReceivedDate": "2023-03-30 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Ovarian Cancer"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "BRCA1"}, {"Gene": "BRCA2"}]}, "Summaries": {"alterationCount": "28", "clinicalTrialCount": "16", "resistiveCount": "0", "sensitizingCount": "0"}, "VariantProperties": {"VariantProperty": [{"geneName": "ARFRP1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "ASXL1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "AURKA", "isVUS": "true", "variantName": "amplification"}, {"geneName": "BCL2L1", "isVUS": "true", "variantName": "amplification"}, {"geneName": "BCORL1", "isVUS": "true", "variantName": "V872G"}, {"geneName": "ERRFI1", "isVUS": "true", "variantName": "P347S"}, {"geneName": "GNAS", "isVUS": "true", "variantName": "amplification"}, {"geneName": "KDM5A", "isVUS": "true", "variantName": "T269N"}, {"geneName": "LYN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "MET", "isVUS": "true", "variantName": "E868K"}, {"geneName": "NBN", "isVUS": "true", "variantName": "amplification"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "S696I"}, {"geneName": "PIK3C2G", "isVUS": "true", "variantName": "D8Y"}, {"geneName": "PRDM1", "isVUS": "true", "variantName": "I573M"}, {"geneName": "RAD21", "isVUS": "true", "variantName": "amplification"}, {"geneName": "SDHB", "isVUS": "true", "variantName": "A271S"}, {"geneName": "SRC", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TSC2", "isVUS": "true", "variantName": "T1330M"}, {"geneName": "WHSC1 (MMSET)", "isVUS": "true", "variantName": "S102T"}, {"geneName": "ZNF217", "isVUS": "true", "variantName": "amplification"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "ARID1A", "Include": "true", "Alterations": {"Alteration": {"Name": "P729fs*15", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "35.41", "isEquivocal": "false", "name": "P729fs*15"}}, "Interpretation": "ARID1A encodes the AT_rich interactive domain_containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor (Guan et al., 2011; 21900401, Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Yan et al., 2014; 24293408, Wang et al., 2012; 22808142, Huang et al., 2012; 22922871, Chan_On et al., 2013; 24185513, Mamo et al., 2012; 21892209). ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss (Jones et al., 2012; 22009941, Wiegand et al., 2010; 20942669, Jones et al., 2010; 20826764, Zang et al., 2012; 22484628, Wang et al., 2011; 22037554), whereas ARID1A missense mutations are mostly uncharacterized. ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46_50%), ovarian and uterine endometrioid carcinomas (24_44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, 2023) (Tate et al., 2019; 30371878, Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Wu et al., 2014; 24618703, Jones et al., 2012; 22009941, Dulak et al., 2013; 23525077, Streppel et al., 2013; 23318448, Jiao et al., 2014; 24293293, Ross et al., 2014; 24563076). ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas (Huang et al., 2014; 25195947, Hussein et al., 2014; 25394778, Bosse et al., 2013; 23702729, Allo et al., 2014; 23887303, Okamura et al., 2020; 32111729), CRC (Chou et al., 2014; 24925223, Ye et al., 2014; 25311944, Wei et al., 2014; 25561809, Okamura et al., 2020; 32111729), and gastric cancer (Chen et al., 2015; 25583476, Wang et al., 2011; 22037554, Abe et al., 2012; 22915242, Wang et al., 2012; 22808142, Wiegand et al., 2014; 24767857, Okamura et al., 2020; 32111729). Several studies have reported no correlation between ARID1A loss and clinicopathological parameters in ovarian clear cell or endometrioid carcinomas or other endometrial cancers (Rahman et al., 2013; 22939958, Maeda et al., 2010; 21614196, Lowery et al., 2012; 22193641, Fadare et al., 2013; 23524907), whereas others suggest that ARID1A loss is a negative prognostic factor (Mao et al., 2013; 24076775, Katagiri et al., 2012; 22101352). There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib (Williamson et al., 2016; 27958275). In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib (Aggarwal et al., 2021; ESMO Abstract 512O). One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan (Thomas et al., 2018; 29252124). In a Phase 1 trial, a patient with metastatic colorectal cancer (CRC) harboring both an ARID1A mutation and ATM loss treated with single_agent M6620 achieved a CR that was ongoing at 29 months (Yap et al., 2020; 32568634). On the basis of limited clinical and preclinical evidence, ARID1A inactivation may predict sensitivity to EZH2 inhibitors (Papadopoulos et al., 2022; ENA Abstract 188, Bitler et al., 2015; 25686104, Kim et al., 2015; 26552009). A Phase 1 study of EZH2 inhibitor CPI_0209 reported 1 PR for a patient with ARID1A_mutated endometrial cancer (Papadopoulos et al., 2022; ENA Abstract 188). Other studies have reported that the loss of ARID1A may activate the PI3K_AKT pathway and be linked with sensitivity to inhibitors of this pathway (Wiegand et al., 2014; 24559118, Huang et al., 2014; 24336158, Samartzis et al., 2014; 24979463). Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti_PD_1 or anti_PD_L1 immunotherapy (Okamura et al., 2020; 32111729). Loss of ARID1A expression has been associated with chemoresistance to platinum_based therapy for patients with ovarian clear cell carcinoma (Yokoyama et al., 2014; 24459582, Katagiri et al., 2012; 22101352) and to 5_fluorouracil in CRC cell lines (Xie et al., 2014; 24833095).", "Include": "true", "ClinicalTrialNote": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT02264678", "Include": "true"}, {"nctId": "NCT04657068", "Include": "true"}, {"nctId": "NCT05327010", "Include": "true"}, {"nctId": "NCT05053971", "Include": "true"}, {"nctId": "NCT05071937", "Include": "true"}, {"nctId": "NCT04266912", "Include": "true"}, {"nctId": "NCT04104776", "Include": "true"}, {"nctId": "NCT04491942", "Include": "true"}, {"nctId": "NCT05252390", "Include": "true"}, {"nctId": "NCT04514497", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "MYC", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "MYC (c_MYC) encodes a transcription factor that regulates many genes related to cell cycle regulation and cell growth. It is an oncogene and may be activated in as many as 20% of cancers (Dang et al., 2006; 16904903). MYC dysregulation (amplification, overexpression, translocation) has been identified in a number of different cancer types (Nesbit et al., 1999; 10378696). MYC amplification has been significantly linked with increased mRNA and protein levels and results in the dysregulation of a large number of target genes (Blancato et al., 2004; 15083194, Dang et al., 2006; 16904903, Fromont et al., 2013; 23574779). Amplification of the MYC gene has been identified in 25_60% of ovarian tumors (cBio_Cancer Genome Atlas Research Network., 2011; 21720365, Prathapam et al., 2010; 20647308, Koboldt et al., 2012; 22300766, Sasano et al., 1990; 1969381, Dimova et al., 2006; 16458500). Overexpression of the MYC protein has been observed in 66% (31/47) of ovarian epithelial tumors (Chen et al., 2005; 16174239). For patients with ovarian carcinoma, MYC amplification has been associated with increased malignancy, higher histological grade, and poorer OS (Katsaros et al., 1995; 7654038, Dimova et al., 2006; 16458500). Limited clinical data indicates that MYC activation may predict sensitivity to the pan_MYC inhibitor OMO_103; a Phase 1 study for patients with solid tumors reported 7 SDs (n=18), including 8% tumor reduction in a patient with pancreas adenocarcinoma (Garralda et al., 2022; ENA Abstract 7). Preclinical data indicate MYC overexpression may predict sensitivity to investigational agents targeting CDK1 (Horiuchi et al., 2012; 22430491, Goga et al., 2007; 17589519), CDK2 (Molenaar et al., 2009; 19525400), Aurora kinase A (Dammert et al., 2019; 31375684, Mollaoglu et al., 2017; 28089889, Robert et al., 2017; 29088717, Wang et al., 2017; 28417568, Takahashi et al., 2015; 25632068, Li et al., 2018; 30226440, Kong et al., 2017; DOI: 10.21037/tcr.2017.06.41, Mahadeva et al., 2014; 24893165, Park et al., 2019; 31429028), Aurora kinase B (Helfrich et al., 2016; 27496133, Hook et al., 2012; 22222631, Yang et al., 2010; 20643922, He et al., 2019; 30540594), glutaminase (Shroff et al., 2015; 25964345, Effenberger et al., 2017; 29156762, Shen et al., 2018; 30103944, Xiang et al., 2015; 25915584), or BET bromodomain_containing proteins (Delmore et al., 2011; 21889194, Bandopadhayay et al., 2013; 24297863, Loven et al., 2013; 23582323, Otto et al., 2019; 31734632), as well as agents targeting both HDAC and PI3K (Dong et al., 2013; 23866964, Pei et al., 2016; 26977882; Fu et al., 2019; 30224636). Exploratory biomarker analysis in a Phase 2 study reported a PFS benefit associated with a combination of the Aurora A kinase inhibitor alisertib and paclitaxel as second_line therapy for patients with MYC_overexpressed small cell lung cancer, but not for patients without MYC overexpression (Owonikoko et al., 2020; 31655296). A PR was reported for a patient with MYC_amplified invasive ductal breast carcinoma treated with an unspecified Aurora kinase inhibitor and taxol (Ganesan et al., 2014; 25253784). MYC amplification has also been suggested to predict response to chemotherapy in patients with breast cancer in some studies (Pereira et al., 2013; 23555992, Yasojima et al., 2011; 21741827). Preclinical evidence suggests that colon cancer cells with MYC amplification may be more sensitive to 5_fluorouracil and paclitaxel (Arango et al., 2001; 11406570, Bottone et al., 2003; 14516787).", "Include": "true", "ClinicalTrialNote": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04553133", "Include": "true"}, {"nctId": "NCT05253053", "Include": "true"}, {"nctId": "NCT04983810", "Include": "true"}, {"nctId": "NCT05327010", "Include": "true"}, {"nctId": "NCT05053971", "Include": "true"}, {"nctId": "NCT05071937", "Include": "true"}, {"nctId": "NCT04555837", "Include": "true"}, {"nctId": "NCT05252390", "Include": "true"}, {"nctId": "NCT04742959", "Include": "true"}, {"nctId": "NCT01434316", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ABL1", "Include": "true", "Alterations": {"Alteration": {"Name": "R589C", "AlterationProperties": {"AlterationProperty": {"dnaFraction": "64.59", "isEquivocal": "false", "name": "R589C"}}, "Interpretation": "ABL1 encodes the Abelson tyrosine protein kinase 1, which is involved in regulating cell growth, motility, and survival (Colicelli, 2010; 20841568, Greuber et al., 2013; 23842646, Bradley and Koleske, 2009; 19759284). ABL1 kinase activation has been reported in several tumor types (Drake et al., 2012; 22307624, Cho et al., 2012; 22521882, Greuber et al., 2013; 23842646). Although activating ABL1 fusions and resistance mutations have been reported in hematological malignancies (Quint\u00e1s_Cardama and Cortes, 2009; 18827185, Soverini et al., 2011; 21562040), the role of ABL1 alterations in solid tumors is unclear (Ganguly and Plattner, 2012; 23226579, Greuber et al., 2013; 23842646). ABL1 mutations have been reported in 0.4_4.0% of colorectal adenocarcinomas (CRC)(Cancer Genome Atlas Network., 2012; 22810696, cBio_Seshagiri et al., 2012; 22895193, Fumagalli et al., 2010; 20233444), 3.2% of uterine corpus endometrial carcinomas (Cancer Genome Atlas Research Network., 2013; 23636398), 2.4% of stomach adenocarcinomas (Cancer Genome Atlas Research Network., 2014; 25079317), 1.7% of lung squamous cell carcinomas (Cancer Genome Atlas Research Network., 2012; 22960745), and less than 1% of lung adenocarcinoma cases (Cancer Genome Atlas Research Network., 2014; 25079552). The prognostic significance of ABL1 alterations in the context of solid tumors is unknown (PubMed, Feb 2023)(Greuber et al., 2013; 23842646). The BCR_ABL fusion protein is the best studied ABL1 alteration and exhibits increased ABL kinase activity; therapies to inhibit activated ABL1 have focused on BCR_ABL_positive hematological malignancies (Ren, 2005; 15719031, O Hare et al., 2012; 22825216). Activating fusions involving ABL1 may be sensitive to ABL inhibitors such as nilotinib, dasatinib, ponatinib, bosutinib, and imatinib (Santos and Quint\u00e1s_Cardama, 2011; 21327563, Reddy and Aggarwal, 2012; 23226582, Soverini et al., 2011; 21562040, Keller_von Amsberg and Br\u00fcmmendorf, 2012; 23098112, Testoni et al., 2016; 26758680). Missense mutations occurring in the BCR_ABL1 kinase domain may contribute to resistance to ABL1 inhibitors (Soverini et al., 2011; 21562040). However, the clinical utility of such therapies in solid tumors is unclear.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "ERBB3", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "ERBB3 (also known as HER3) encodes a member of the epidermal growth factor receptor (EGFR) family (Sheng et al., 2011; 21364581). One study has demonstrated a weak but significant association between ERBB3 gene amplification and ERBB3 protein expression in breast cancer tissue (Sassen et al., 2008; 18182100). In the Ovarian Serous Cystadenocarcinoma TCGA dataset, ERBB3 amplification and mutation were detected in 4% and <1% of cases, respectively (Cancer Genome Atlas Research Network., 2011; 21720365). In the literature, overexpression of ERBB3 protein has been detected in 53_76% of ovarian carcinomas (Davies et al., 2014; 24901400, Tanner et al., 2006; 16896008). ERBB3 protein overexpression in ovarian cancer has been correlated with poor prognosis (Tanner et al., 2006; 16896008, Leng et al., 1997; 11324501, Sithanandam and Anderson, 2008; 18404164). ERBB3 cooperates with other ERBB family members, in particular ERBB2, for efficient signaling (Black et al., 2019; 31351986, Baselga and Swain, 2009; 19536107, Jaiswal et al., 2013; 23680147, Jura et al., 2009; 20007378). Therefore, ERBB3 amplification or activating mutation may predict sensitivity to therapies targeting ERBB2, including antibodies such as trastuzumab, pertuzumab, and ado_trastuzumab emtansine (T_DM1), and dual EGFR/HER2 TKIs such as lapatinib and afatinib. Clinical and preclinical data support sensitivity of ERBB3 activating mutations to various anti_ERBB2 agents (Choudhury et al., 2016; 27044931, Verlingue et al., 2018; 29413684, Bidard et al., 2015; 25953157, Jaiswal et al., 2013; 23680147, Umelo et al., 2016; 26689995, Mishra et al., 2018; 29963236), but data are generally limited for ERBB3 amplification. Biomarker analyses of several Phase 3 trials have not identified an association of ERBB3 expression levels with benefit from trastuzumab_, pertuzumab_, or T_DM1_containing regimens in HER2_positive breast cancer (Perez et al., 2019; 31146717, Baselga et al., 2014; 25332247, Kim et al., 2016; 27428671, Baselga et al., 2016; 26920887), T_DM1 in HER2_positive gastric and gastroesophageal junction (GEJ) cancer (Shah et al., 2019; 30706247), pertuzumab combined with chemotherapy in ovarian cancer (Kurzeder et al., 2016; 27269942), or afatinib in HNSCC (Cohen et al., 2017; 28961833). Similarly, ERBB3 expression levels were not associated with PFS or OS from lapatinib plus capecitabine in a Phase 2 study of gastric/GEJ cancer (LaBonte et al., 2016; 27325685) or in retrospective studies of HER2_positive breast cancer (Nishimura et al., 2017; 28478451, Duchnowska et al., 2017; 29262628, Fabi et al., 2013; 23472669).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Homologous Recombination status", "Include": "true", "Alterations": {"Alteration": {"Name": "HRD Not Detected", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "HRD Not Detected"}}, "Interpretation": null, "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Loss of Heterozygosity score", "Include": "true", "Alterations": {"Alteration": {"Name": "LOH_Low", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "LOH_Low"}}, "Interpretation": "The loss of heterozygosity (LOH) score is a profile of the percentage of the tumor genome that is under focal loss of one allele (Swisher et al., 2016; 27908594); focal LOH events accumulate as genomic \"scars\" as a result of incorrect DNA double_strand break repair when the homologous recombination pathway is deficient (HRD) (Abkevich et al., 2012; 23047548, Wang et al., 2012; 22912389, Watkins et al., 2014; 25093514, Vanderstichele et al., 2017; 28950147). HRD and consequent genomic LOH occur as a result of genetic or epigenetic inactivation of one or more of the homologous recombination pathway proteins, including BRCA1, BRCA2, RAD51C, ATM, PALB2, and BRIP1 (Vanderstichele et al., 2017; 28950147, Watkins et al., 2014; 25093514, Cancer Genome Atlas Research Network., 2011; 21720365, Venkitaraman, 2003; 12736286). This sample harbors a genomic LOH score below levels that have been associated with improved rates of clinical benefit from treatment with the PARP inhibitor rucaparib in patients with platinum_sensitive, BRCA1/2 wild_type ovarian, peritoneal, or Fallopian tube carcinoma (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). However, patients with lower genomic LOH have also responded to rucaparib, and this type of LOH score does not preclude benefit from PARP inhibitors (Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In a study of more than 4,000 ovarian, Fallopian tube, or peritoneal cancer samples, genomic LOH score \u2265 16% was identified in 24.2% of BRCA1/2 wild_type cases, deleterious BRCA1/2 mutation was identified in an additional 17.2% of cases, and the remaining 58.7% of cases had LOH score < 16% and were BRCA1/2 wild_type (Elvin et al., 2017; ASCO Abstract 5512). Among the histological subtypes, LOH score \u2265 16% or BRCA1/2 mutation was reported in 42.4% of serous carcinomas, 37.6% of endometrioid carcinomas, 23.5% of carcinosarcomas, 20.6% of neuroendocrine carcinomas, 13.6% of clear cell carcinomas, and 8.1% of mucinous carcinomas; in BRCA1/2 wild_type samples, the median LOH score was significantly higher in serous as compared with non_serous cases (Elvin et al., 2017; ASCO Abstract 5512). In ovarian carcinoma, the median LOH score is significantly higher for BRCA1/2_mutated cases than BRCA1/2 wild_type cases (22.2% vs. 9.8%) (Elvin et al., 2017; ASCO Abstract 5512), and mutation or methylation of BRCA1, BRCA2, or RAD51C has been reported to be enriched in cases with increased genomic LOH (Wang et al., 2012; 22912389, Abkevich et al., 2012; 23047548). One study reported no association between LOH and either tumor stage or grade in ovarian serous carcinoma (Marquard et al., 2015; 26015868). In patients with high_grade serous ovarian carcinoma, the frequency of LOH has been reported to increase significantly with age (Pedersen et al., 2013; 23716468). On the basis of emerging clinical data in ovarian cancer, elevated genomic LOH may be associated with greater sensitivity to PARP inhibitors (Coleman et al., 2016; ASCO Abstract 5540, Coleman et al., 2017; 28916367, Swisher et al., 2016; 27908594). In platinum_sensitive, BRCA1/2 wild_type ovarian, peritoneal, or Fallopian tube carcinoma, rucaparib elicited significantly longer median PFS (7.2 vs. 5.0 months, HR=0.51) and improved ORR (33.3% vs. 9.6%, p=0.0003) for patients with LOH score \u2265 16% (Coleman et al., 2016; ASCO Abstract 5540, Swisher et al., 2016; 27908594). In the maintenance setting in platinum_sensitive, BRCA1/2 wild_type patients, rucaparib was superior to placebo in both the LOH score \u2265 16% (median PFS, 9.7 vs. 5.4 months; HR=0.44) and LOH score < 16% (median PFS, 6.7 vs. 5.4 months; HR=0.58) cohorts (Coleman et al., 2017; 28916367). Similar results have been reported for maintenance treatment with niraparib in ovarian cancer (Mirza et al., 2016; 27717299) when using a different measure of HRD that includes genomic LOH (Telli et al., 2016; 26957554, Timms et al., 2014; 25475740). Increased LOH has also been associated with improved sensitivity to platinum_containing chemotherapy regimens in patients with ovarian or breast cancer (Wang et al., 2012; 22912389, Telli et al., 2015; 25847929, Isakoff et al., 2015; 25847936).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSI_high (MSI_H) has been reported in 1.6_19.7% of ovarian cancer samples (Segev et al., 2015; 26775351, Plisiecka_Ha\u0142asa et al., 2008; 18507046), including 3.8% (1/26) of ovarian endometrioid adenocarcinomas (Huang et al., 2015; 25195947), and 10.0% (3/30) of ovarian clear cell carcinomas (CCOCs) (Strickland et al., 2016; ASCO Abstract 5514). No association of MSI_H with stage or survival was found in patients with ovarian cancer (Segev et al., 2015; 26775351, Aysal et al., 2012; 22189970). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "05", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "05"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Ovarian clear cell carcinoma harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 1.7% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). In a study of high grade serous ovarian cancer, homologous recombination (HR)_deficient tumors, which comprised ~50% of all samples, harbored a higher neoantigen load compared to HR_proficient tumors; higher neoantigen load was associated with longer OS but not disease free survival (Strickland et al., 2016; 26871470). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "StudyPhase": "PHASE 1/2", "Target": "ATR, PARP, PD_L1", "Locations": "Seongnam_si (Korea, Republic of), Seoul (Korea, Republic of), Goyang_si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)", "NCTID": "NCT02264678", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR", "Locations": "London (United Kingdom), Colorado, Oklahoma, Texas, Pennsylvania, Tennessee, Florida", "NCTID": "NCT04657068", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Testing the Combination of the Anti_cancer Drugs ZEN003694 (ZEN_3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial", "StudyPhase": "PHASE 2", "Target": "PARP, BRD4, BRDT, BRD2, BRD3", "Locations": "Illinois, Texas, Georgia", "NCTID": "NCT05327010", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Testing A New Anti_cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1/2", "Target": "BRD3, BRD4, BRD2, BRDT, HDAC", "Locations": "Oklahoma, Connecticut, Florida", "NCTID": "NCT05053971", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer", "StudyPhase": "PHASE 2", "Target": "BRD4, BRDT, BRD2, BRD3, PARP", "Locations": "Pennsylvania", "NCTID": "NCT05071937", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "ATR, PD_L1", "Locations": "Texas", "NCTID": "NCT04266912", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "A Study of CPI_0209 in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "EZH2, TOP1", "Locations": "Washington, Salamanca (Spain), Michigan, Illinois, Ohio, Massachusetts, New Jersey, New York", "NCTID": "NCT04104776", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer", "StudyPhase": "PHASE 1", "Target": "ATR", "Locations": "California, Wisconsin, Toronto (Canada), Ohio, Pennsylvania, Maryland", "NCTID": "NCT04491942", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "NUV_868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRD4, PARP, AR", "Locations": "Montana, California, Arizona, Michigan, Texas, Tennessee, Maryland, Virginia, North Carolina", "NCTID": "NCT05252390", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "ARID1A", "Alteration": "P729fs*15", "Title": "Testing the Addition of an Anti_cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "StudyPhase": "PHASE 1", "Target": "TOP1, ATR", "Locations": "Arizona, Minnesota, Oklahoma, Missouri, Pennsylvania, Connecticut, New York, Tennessee, Florida", "NCTID": "NCT04514497", "Note": "ARID1A loss or inactivation may predict sensitivity to ATR inhibitors. On the basis of preclinical evidence, ARID1A loss or inactivation may predict sensitivity to EZH2 and BET/BRD inhibitors.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "PF_07104091 as a Single Agent and in Combination Therapy", "StudyPhase": "PHASE 1/2", "Target": "CDK6, Aromatase, CDK4, CDK2", "Locations": "Shanghai (China), Koto (Japan), Kashiwa (Japan), Iowa, Michigan, Massachusetts, Kentucky, New York", "NCTID": "NCT04553133", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Study to Evaluate the Efficacy and Safety of TT_00420 as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, Aurora kinase B, PD_L1", "Locations": "Jinan (China), Beijing (China)", "NCTID": "NCT05253053", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma", "StudyPhase": "PHASE 1/2", "Target": "CDK2, CDK9", "Locations": "Seoul (Korea, Republic of), Barcelona (Spain), California, Texas", "NCTID": "NCT04983810", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing the Combination of the Anti_cancer Drugs ZEN003694 (ZEN_3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial", "StudyPhase": "PHASE 2", "Target": "PARP, BRD4, BRDT, BRD2, BRD3", "Locations": "Illinois, Texas, Georgia", "NCTID": "NCT05327010", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Testing A New Anti_cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas", "StudyPhase": "PHASE 1/2", "Target": "BRD3, BRD4, BRD2, BRDT, HDAC", "Locations": "Oklahoma, Connecticut, Florida", "NCTID": "NCT05053971", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer", "StudyPhase": "PHASE 2", "Target": "BRD4, BRDT, BRD2, BRD3, PARP", "Locations": "Pennsylvania", "NCTID": "NCT05071937", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Alisertib and Pembrolizumab for the Treatment of Patients With Rb_deficient Head and Neck Squamous Cell Cancer", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, PD_1", "Locations": "Texas", "NCTID": "NCT04555837", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "NUV_868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "BRD4, PARP, AR", "Locations": "Montana, California, Arizona, Michigan, Texas, Tennessee, Maryland, Virginia, North Carolina", "NCTID": "NCT05252390", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Crossover Relative Bioavailability and Dose Escalation Study of TT_00420 Tablet in Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1/2", "Target": "Aurora kinase A, Aurora kinase B", "Locations": "California, Illinois, Ohio, Texas, New Jersey", "NCTID": "NCT04742959", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}, {"Gene": "MYC", "Alteration": "amplification", "Title": "Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors", "StudyPhase": "PHASE 1", "Target": "PARP, CDK1, CDK9, CDK5, CDK2", "Locations": "Massachusetts", "NCTID": "NCT01434316", "Note": "MYC overexpression may predict sensitivity to inhibition of CDKs, especially CDK1 and CDK2, of Aurora kinases, including Aurora kinase A and B, and of BET domain proteins, which are reported to downregulate MYC expression and MYC_dependent transcriptional programs.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "21900401", "FullCitation": "Guan B, et al. Cancer Res. (2011) pmid: 21900401", "Include": "true"}, {"number": "1", "ReferenceId": "22009941", "FullCitation": "Jones S, et al. Hum. Mutat. (2012) pmid: 22009941", "Include": "true"}, {"number": "2", "ReferenceId": "20942669", "FullCitation": "Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669", "Include": "true"}, {"number": "3", "ReferenceId": "20826764", "FullCitation": "Jones S, et al. Science (2010) pmid: 20826764", "Include": "true"}, {"number": "4", "ReferenceId": "24293408", "FullCitation": "Yan HB, et al. Carcinogenesis (2014) pmid: 24293408", "Include": "true"}, {"number": "5", "ReferenceId": "22808142", "FullCitation": "Wang DD, et al. PLoS ONE (2012) pmid: 22808142", "Include": "true"}, {"number": "6", "ReferenceId": "22922871", "FullCitation": "Huang J, et al. Nat. Genet. (2012) pmid: 22922871", "Include": "true"}, {"number": "7", "ReferenceId": "24185513", "FullCitation": "Chan_On W, et al. Nat. Genet. (2013) pmid: 24185513", "Include": "true"}, {"number": "8", "ReferenceId": "21892209", "FullCitation": "Mamo A, et al. Oncogene (2012) pmid: 21892209", "Include": "true"}, {"number": "9", "ReferenceId": "22484628", "FullCitation": "Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628", "Include": "true"}, {"number": "10", "ReferenceId": "22037554", "FullCitation": "Wang K, et al. Nat. Genet. (2011) pmid: 22037554", "Include": "true"}, {"number": "11", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "12", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "13", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "14", "ReferenceId": "24618703", "FullCitation": "Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703", "Include": "true"}, {"number": "15", "ReferenceId": "23525077", "FullCitation": "Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077", "Include": "true"}, {"number": "16", "ReferenceId": "23318448", "FullCitation": "Streppel MM, et al. Oncogene (2014) pmid: 23318448", "Include": "true"}, {"number": "17", "ReferenceId": "24293293", "FullCitation": "Jiao Y, et al. J. Pathol. (2014) pmid: 24293293", "Include": "true"}, {"number": "18", "ReferenceId": "24563076", "FullCitation": "Ross JS, et al. Oncologist (2014) pmid: 24563076", "Include": "true"}, {"number": "19", "ReferenceId": "25195947", "FullCitation": "Huang HN, et al. Histopathology (2015) pmid: 25195947", "Include": "true"}, {"number": "20", "ReferenceId": "25394778", "FullCitation": "Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778", "Include": "true"}, {"number": "21", "ReferenceId": "23702729", "FullCitation": "Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729", "Include": "true"}, {"number": "22", "ReferenceId": "23887303", "FullCitation": "Allo G, et al. Mod. Pathol. (2014) pmid: 23887303", "Include": "true"}, {"number": "23", "ReferenceId": "32111729", "FullCitation": "Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729", "Include": "true"}, {"number": "24", "ReferenceId": "24925223", "FullCitation": "Chou A, et al. Hum. Pathol. (2014) pmid: 24925223", "Include": "true"}, {"number": "25", "ReferenceId": "25311944", "FullCitation": "Ye J, et al. Hum. Pathol. (2014) pmid: 25311944", "Include": "true"}, {"number": "26", "ReferenceId": "25561809", "FullCitation": "Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809", "Include": "true"}, {"number": "27", "ReferenceId": "25583476", "FullCitation": "Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476", "Include": "true"}, {"number": "28", "ReferenceId": "22915242", "FullCitation": "Abe H, et al. Virchows Arch. (2012) pmid: 22915242", "Include": "true"}, {"number": "29", "ReferenceId": "24767857", "FullCitation": "Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857", "Include": "true"}, {"number": "30", "ReferenceId": "22939958", "FullCitation": "Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958", "Include": "true"}, {"number": "31", "ReferenceId": "21614196", "FullCitation": "Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196", "Include": "true"}, {"number": "32", "ReferenceId": "22193641", "FullCitation": "Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641", "Include": "true"}, {"number": "33", "ReferenceId": "23524907", "FullCitation": "Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907", "Include": "true"}, {"number": "34", "ReferenceId": "24076775", "FullCitation": "Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775", "Include": "true"}, {"number": "35", "ReferenceId": "22101352", "FullCitation": "Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352", "Include": "true"}, {"number": "36", "ReferenceId": "27958275", "FullCitation": "Williamson CT, et al. Nat Commun (2016) pmid: 27958275", "Include": "true"}, {"number": "37", "ReferenceId": "29252124", "FullCitation": "Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124", "Include": "true"}, {"number": "38", "ReferenceId": "32568634", "FullCitation": "Yap TA, et al. J Clin Oncol (2020) pmid: 32568634", "Include": "true"}, {"number": "39", "ReferenceId": "25686104", "FullCitation": "Bitler BG, et al. Nat. Med. (2015) pmid: 25686104", "Include": "true"}, {"number": "40", "ReferenceId": "26552009", "FullCitation": "Kim KH, et al. Nat. Med. (2015) pmid: 26552009", "Include": "true"}, {"number": "41", "ReferenceId": "24559118", "FullCitation": "Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118", "Include": "true"}, {"number": "42", "ReferenceId": "24336158", "FullCitation": "Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158", "Include": "true"}, {"number": "43", "ReferenceId": "24979463", "FullCitation": "Samartzis EP, et al. Oncotarget (2014) pmid: 24979463", "Include": "true"}, {"number": "44", "ReferenceId": "24459582", "FullCitation": "Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582", "Include": "true"}, {"number": "45", "ReferenceId": "24833095", "FullCitation": "Xie C, et al. Tumour Biol. (2014) pmid: 24833095", "Include": "true"}, {"number": "46", "ReferenceId": "16904903", "FullCitation": "Dang CV, et al. Semin. Cancer Biol. (2006) pmid: 16904903", "Include": "true"}, {"number": "47", "ReferenceId": "10378696", "FullCitation": "Nesbit CE, et al. Oncogene (1999) pmid: 10378696", "Include": "true"}, {"number": "48", "ReferenceId": "15083194", "FullCitation": "Blancato J, et al. Br. J. Cancer (2004) pmid: 15083194", "Include": "true"}, {"number": "49", "ReferenceId": "23574779", "FullCitation": "Fromont G, et al. Hum. Pathol. (2013) pmid: 23574779", "Include": "true"}, {"number": "50", "ReferenceId": "21720365", "FullCitation": "Nature (2011) pmid: 21720365", "Include": "true"}, {"number": "51", "ReferenceId": "20647308", "FullCitation": "Prathapam T, et al. J. Biol. Chem. (2010) pmid: 20647308", "Include": "true"}, {"number": "52", "ReferenceId": "22300766", "FullCitation": "Koboldt DC, et al. Genome Res. (2012) pmid: 22300766", "Include": "true"}, {"number": "53", "ReferenceId": "1969381", "FullCitation": "Sasano H, et al. Hum. Pathol. (1990) pmid: 1969381", "Include": "true"}, {"number": "54", "ReferenceId": "16458500", "FullCitation": "Dimova I, et al. Eur. J. Cancer (2006) pmid: 16458500", "Include": "true"}, {"number": "55", "ReferenceId": "16174239", "FullCitation": "Chen CH, et al. Int. J. Gynecol. Cancer () pmid: 16174239", "Include": "true"}, {"number": "56", "ReferenceId": "7654038", "FullCitation": "Katsaros D, et al. Anticancer Res. () pmid: 7654038", "Include": "true"}, {"number": "57", "ReferenceId": "22430491", "FullCitation": "Horiuchi D, et al. J. Exp. Med. (2012) pmid: 22430491", "Include": "true"}, {"number": "58", "ReferenceId": "17589519", "FullCitation": "Goga A, et al. Nat. Med. (2007) pmid: 17589519", "Include": "true"}, {"number": "59", "ReferenceId": "19525400", "FullCitation": "Molenaar JJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19525400", "Include": "true"}, {"number": "60", "ReferenceId": "31375684", "FullCitation": "Dammert MA, et al. Nat Commun (2019) pmid: 31375684", "Include": "true"}, {"number": "61", "ReferenceId": "28089889", "FullCitation": "Mollaoglu G, et al. Cancer Cell (2017) pmid: 28089889", "Include": "true"}, {"number": "62", "ReferenceId": "29088717", "FullCitation": "Cardnell RJ, et al. Oncotarget (2017) pmid: 29088717", "Include": "true"}, {"number": "63", "ReferenceId": "28417568", "FullCitation": "Wang L, et al. Mol Oncol (2017) pmid: 28417568", "Include": "true"}, {"number": "64", "ReferenceId": "25632068", "FullCitation": "Takahashi Y, et al. Ann. Oncol. (2015) pmid: 25632068", "Include": "true"}, {"number": "65", "ReferenceId": "30226440", "FullCitation": "Li Y, et al. Thyroid (2018) pmid: 30226440", "Include": "true"}, {"number": "66", "ReferenceId": "24893165", "FullCitation": "Mahadevan D, et al. PLoS ONE (2014) pmid: 24893165", "Include": "true"}, {"number": "67", "ReferenceId": "31429028", "FullCitation": "Park SI, et al. Target Oncol (2019) pmid: 31429028", "Include": "true"}, {"number": "68", "ReferenceId": "27496133", "FullCitation": "Helfrich BA, et al. Mol. Cancer Ther. (2016) pmid: 27496133", "Include": "true"}, {"number": "69", "ReferenceId": "22222631", "FullCitation": "Hook KE, et al. Mol. Cancer Ther. (2012) pmid: 22222631", "Include": "true"}, {"number": "70", "ReferenceId": "20643922", "FullCitation": "Yang D, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20643922", "Include": "true"}, {"number": "71", "ReferenceId": "30540594", "FullCitation": "He J, et al. Anticancer Drugs (2019) pmid: 30540594", "Include": "true"}, {"number": "72", "ReferenceId": "25964345", "FullCitation": "Shroff EH, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25964345", "Include": "true"}, {"number": "73", "ReferenceId": "29156762", "FullCitation": "Effenberger M, et al. Oncotarget (2017) pmid: 29156762", "Include": "true"}, {"number": "74", "ReferenceId": "30103944", "FullCitation": "Qu X, et al. Biochem. Biophys. Res. Commun. (2018) pmid: 30103944", "Include": "true"}, {"number": "75", "ReferenceId": "25915584", "FullCitation": "Xiang Y, et al. J. Clin. Invest. (2015) pmid: 25915584", "Include": "true"}, {"number": "76", "ReferenceId": "21889194", "FullCitation": "Delmore JE, et al. Cell (2011) pmid: 21889194", "Include": "true"}, {"number": "77", "ReferenceId": "24297863", "FullCitation": "Bandopadhayay P, et al. Clin. Cancer Res. (2014) pmid: 24297863", "Include": "true"}, {"number": "78", "ReferenceId": "23582323", "FullCitation": "Lov\u00e9n J, et al. Cell (2013) pmid: 23582323", "Include": "true"}, {"number": "79", "ReferenceId": "31734632", "FullCitation": "Otto C, et al. Neoplasia (2019) pmid: 31734632", "Include": "true"}, {"number": "80", "ReferenceId": "23866964", "FullCitation": "Dong LH, et al. J Hematol Oncol (2013) pmid: 23866964", "Include": "true"}, {"number": "81", "ReferenceId": "26977882", "FullCitation": "Pei Y, et al. Cancer Cell (2016) pmid: 26977882", "Include": "true"}, {"number": "82", "ReferenceId": "30224636", "FullCitation": "Fu XH, et al. Acta Pharmacol. Sin. (2019) pmid: 30224636", "Include": "true"}, {"number": "83", "ReferenceId": "31655296", "FullCitation": "Owonikoko TK, et al. J Thorac Oncol (2020) pmid: 31655296", "Include": "true"}, {"number": "84", "ReferenceId": "25253784", "FullCitation": "Ganesan P, et al. Mol. Cancer Ther. (2014) pmid: 25253784", "Include": "true"}, {"number": "85", "ReferenceId": "23555992", "FullCitation": "Pereira CB, et al. PLoS ONE (2013) pmid: 23555992", "Include": "true"}, {"number": "86", "ReferenceId": "21741827", "FullCitation": "Yasojima H, et al. Eur. J. Cancer (2011) pmid: 21741827", "Include": "true"}, {"number": "87", "ReferenceId": "11406570", "FullCitation": "Arango D, et al. Cancer Res. (2001) pmid: 11406570", "Include": "true"}, {"number": "88", "ReferenceId": "14516787", "FullCitation": "Bottone MG, et al. Exp. Cell Res. (2003) pmid: 14516787", "Include": "true"}, {"number": "89", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "90", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "91", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "92", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "93", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "94", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "95", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "96", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "97", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "98", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "99", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "100", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "101", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "102", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "103", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "104", "ReferenceId": "26871470", "FullCitation": "Strickland KC, et al. Oncotarget (2016) pmid: 26871470", "Include": "true"}, {"number": "105", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "106", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "107", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "108", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "109", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "110", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "111", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "112", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "113", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "114", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "115", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "116", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "117", "ReferenceId": "27908594", "FullCitation": "Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594", "Include": "true"}, {"number": "118", "ReferenceId": "23047548", "FullCitation": "Abkevich V, et al. Br. J. Cancer (2012) pmid: 23047548", "Include": "true"}, {"number": "119", "ReferenceId": "22912389", "FullCitation": "Wang ZC, et al. Clin. Cancer Res. (2012) pmid: 22912389", "Include": "true"}, {"number": "120", "ReferenceId": "25093514", "FullCitation": "Watkins JA, et al. Breast Cancer Res. (2014) pmid: 25093514", "Include": "true"}, {"number": "121", "ReferenceId": "28950147", "FullCitation": "Vanderstichele A, et al. Eur. J. Cancer (2017) pmid: 28950147", "Include": "true"}, {"number": "122", "ReferenceId": "12736286", "FullCitation": "N. Engl. J. Med. (2003) pmid: 12736286", "Include": "true"}, {"number": "123", "ReferenceId": "28916367", "FullCitation": "Coleman RL, et al. Lancet (2017) pmid: 28916367", "Include": "true"}, {"number": "124", "ReferenceId": "26015868", "FullCitation": "Marquard AM, et al. Biomark Res (2015) pmid: 26015868", "Include": "true"}, {"number": "125", "ReferenceId": "23716468", "FullCitation": "Pedersen BS, et al. Genes Chromosomes Cancer (2013) pmid: 23716468", "Include": "true"}, {"number": "126", "ReferenceId": "27717299", "FullCitation": "Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299", "Include": "true"}, {"number": "127", "ReferenceId": "26957554", "FullCitation": "Telli ML, et al. Clin. Cancer Res. (2016) pmid: 26957554", "Include": "true"}, {"number": "128", "ReferenceId": "25475740", "FullCitation": "Timms KM, et al. Breast Cancer Res. (2014) pmid: 25475740", "Include": "true"}, {"number": "129", "ReferenceId": "25847929", "FullCitation": "Telli ML, et al. J. Clin. Oncol. (2015) pmid: 25847929", "Include": "true"}, {"number": "130", "ReferenceId": "25847936", "FullCitation": "Isakoff SJ, et al. J. Clin. Oncol. (2015) pmid: 25847936", "Include": "true"}, {"number": "131", "ReferenceId": "21364581", "FullCitation": "Sheng Q, et al. Br. J. Cancer (2011) pmid: 21364581", "Include": "true"}, {"number": "132", "ReferenceId": "18182100", "FullCitation": "Sassen A, et al. Breast Cancer Res. (2008) pmid: 18182100", "Include": "true"}, {"number": "133", "ReferenceId": "24901400", "FullCitation": "Davies S, et al. Int. J. Gynecol. Pathol. (2014) pmid: 24901400", "Include": "true"}, {"number": "134", "ReferenceId": "16896008", "FullCitation": "Tanner B, et al. J. Clin. Oncol. (2006) pmid: 16896008", "Include": "true"}, {"number": "135", "ReferenceId": "11324501", "FullCitation": "Leng J, et al. Chin. Med. Sci. J. (1997) pmid: 11324501", "Include": "true"}, {"number": "136", "ReferenceId": "18404164", "FullCitation": "Sithanandam G, et al. Cancer Gene Ther. (2008) pmid: 18404164", "Include": "true"}, {"number": "137", "ReferenceId": "31351986", "FullCitation": "Black LE, et al. Am. J. Pathol. (2019) pmid: 31351986", "Include": "true"}, {"number": "138", "ReferenceId": "19536107", "FullCitation": "Baselga J, et al. Nat. Rev. Cancer (2009) pmid: 19536107", "Include": "true"}, {"number": "139", "ReferenceId": "23680147", "FullCitation": "Jaiswal BS, et al. Cancer Cell (2013) pmid: 23680147", "Include": "true"}, {"number": "140", "ReferenceId": "20007378", "FullCitation": "Jura N, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 20007378", "Include": "true"}, {"number": "141", "ReferenceId": "27044931", "FullCitation": "Choudhury NJ, et al. J. Clin. Oncol. (2016) pmid: 27044931", "Include": "true"}, {"number": "142", "ReferenceId": "29413684", "FullCitation": "Verlingue L, et al. Eur. J. Cancer (2018) pmid: 29413684", "Include": "true"}, {"number": "143", "ReferenceId": "25953157", "FullCitation": "Bidard FC, et al. Ann. Oncol. (2015) pmid: 25953157", "Include": "true"}, {"number": "144", "ReferenceId": "26689995", "FullCitation": "Umelo I, et al. Oncotarget (2016) pmid: 26689995", "Include": "true"}, {"number": "145", "ReferenceId": "29963236", "FullCitation": "Mishra R, et al. Oncotarget (2018) pmid: 29963236", "Include": "true"}, {"number": "146", "ReferenceId": "31146717", "FullCitation": "Perez EA, et al. BMC Cancer (2019) pmid: 31146717", "Include": "true"}, {"number": "147", "ReferenceId": "25332247", "FullCitation": "Baselga J, et al. J. Clin. Oncol. (2014) pmid: 25332247", "Include": "true"}, {"number": "148", "ReferenceId": "27428671", "FullCitation": "Kim SB, et al. Int. J. Cancer (2016) pmid: 27428671", "Include": "true"}, {"number": "149", "ReferenceId": "26920887", "FullCitation": "Baselga J, et al. Clin. Cancer Res. (2016) pmid: 26920887", "Include": "true"}, {"number": "150", "ReferenceId": "30706247", "FullCitation": "Shah MA, et al. Gastric Cancer (2019) pmid: 30706247", "Include": "true"}, {"number": "151", "ReferenceId": "27269942", "FullCitation": "Kurzeder C, et al. J. Clin. Oncol. (2016) pmid: 27269942", "Include": "true"}, {"number": "152", "ReferenceId": "28961833", "FullCitation": "Cohen EEW, et al. Ann. Oncol. (2017) pmid: 28961833", "Include": "true"}, {"number": "153", "ReferenceId": "27325685", "FullCitation": "LaBonte MJ, et al. Mol. Cancer Ther. (2016) pmid: 27325685", "Include": "true"}, {"number": "154", "ReferenceId": "28478451", "FullCitation": "Nishimura R, et al. Oncology (2017) pmid: 28478451", "Include": "true"}, {"number": "155", "ReferenceId": "29262628", "FullCitation": "Duchnowska R, et al. Oncotarget (2017) pmid: 29262628", "Include": "true"}, {"number": "156", "ReferenceId": "23472669", "FullCitation": "Fabi A, et al. Expert Opin Pharmacother (2013) pmid: 23472669", "Include": "true"}, {"number": "157", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "158", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "159", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "160", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "161", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "162", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "163", "ReferenceId": "26775351", "FullCitation": "Segev Y, et al. Eur. J. Gynaecol. Oncol. (2015) pmid: 26775351", "Include": "true"}, {"number": "164", "ReferenceId": "18507046", "FullCitation": "Plisiecka_Ha\u0142asa J, et al. Anticancer Res. () pmid: 18507046", "Include": "true"}, {"number": "165", "ReferenceId": "22189970", "FullCitation": "Aysal A, et al. Am. J. Surg. Pathol. (2012) pmid: 22189970", "Include": "true"}, {"number": "166", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "167", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "168", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "169", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "170", "ReferenceId": "20841568", "FullCitation": "Sci Signal (2010) pmid: 20841568", "Include": "true"}, {"number": "171", "ReferenceId": "23842646", "FullCitation": "Greuber EK, et al. Nat. Rev. Cancer (2013) pmid: 23842646", "Include": "true"}, {"number": "172", "ReferenceId": "19759284", "FullCitation": "Bradley WD, et al. J. Cell. Sci. (2009) pmid: 19759284", "Include": "true"}, {"number": "173", "ReferenceId": "22307624", "FullCitation": "Drake JM, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22307624", "Include": "true"}, {"number": "174", "ReferenceId": "22521882", "FullCitation": "Cho NL, et al. Biochem. Biophys. Res. Commun. (2012) pmid: 22521882", "Include": "true"}, {"number": "175", "ReferenceId": "18827185", "FullCitation": "Quint\u00e1s_Cardama A, et al. Blood (2009) pmid: 18827185", "Include": "true"}, {"number": "176", "ReferenceId": "21562040", "FullCitation": "Soverini S, et al. Blood (2011) pmid: 21562040", "Include": "true"}, {"number": "177", "ReferenceId": "23226579", "FullCitation": "Ganguly SS, et al. Genes Cancer (2012) pmid: 23226579", "Include": "true"}, {"number": "178", "ReferenceId": "22895193", "FullCitation": "Seshagiri S, et al. Nature (2012) pmid: 22895193", "Include": "true"}, {"number": "179", "ReferenceId": "20233444", "FullCitation": "Fumagalli D, et al. BMC Cancer (2010) pmid: 20233444", "Include": "true"}, {"number": "180", "ReferenceId": "25079317", "FullCitation": "Nature (2014) pmid: 25079317", "Include": "true"}, {"number": "181", "ReferenceId": "22960745", "FullCitation": "Nature (2012) pmid: 22960745", "Include": "true"}, {"number": "182", "ReferenceId": "25079552", "FullCitation": "Nature (2014) pmid: 25079552", "Include": "true"}, {"number": "183", "ReferenceId": "15719031", "FullCitation": "Nat. Rev. Cancer (2005) pmid: 15719031", "Include": "true"}, {"number": "184", "ReferenceId": "22825216", "FullCitation": "O Hare T, et al. Nat. Rev. Cancer (2012) pmid: 22825216", "Include": "true"}, {"number": "185", "ReferenceId": "21327563", "FullCitation": "Santos FP, et al. Curr Hematol Malig Rep (2011) pmid: 21327563", "Include": "true"}, {"number": "186", "ReferenceId": "23226582", "FullCitation": "Reddy EP, et al. Genes Cancer (2012) pmid: 23226582", "Include": "true"}, {"number": "187", "ReferenceId": "23098112", "FullCitation": "Keller_V Amsberg G, et al. Expert Rev Anticancer Ther (2012) pmid: 23098112", "Include": "true"}, {"number": "188", "ReferenceId": "26758680", "FullCitation": "Testoni E, et al. EMBO Mol Med (2016) pmid: 26758680", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_03_21 16:33:30", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "973x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "5 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "4.4%"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "OVARY", "disease_ontology": "Ovary clear cell carcinoma", "flowcell_analysis": "2000028241", "gender": "female", "pathology_diagnosis": "Ovarian Clear Cell Carcinoma", "percent_tumor_nuclei": "35", "pipeline_version": "v3.20.0", "purity_assessment": "38.28", "specimen": "ORD_1587798_01*US1517083.01", "study": "CLINICAL_F1CDx v2", "test_request": "ORD_1587798_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Ovary", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX2", "mean_exon_depth": "999.41", "name": "SQ_US1517083.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.1957", "cds_effect": "2602G>A", "depth": "608", "equivocal": "false", "functional_effect": "missense", "gene": "MET", "percent_reads": "19.57", "position": "chr7:116409717", "protein_effect": "E868K", "status": "unknown", "strand": "+", "transcript": "NM_000245", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.3856", "cds_effect": "2087G>T", "depth": "931", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "38.56", "position": "chr19:15296355", "protein_effect": "S696I", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.5859", "cds_effect": "2615T>G", "depth": "797", "equivocal": "false", "functional_effect": "missense", "gene": "BCORL1", "percent_reads": "58.59", "position": "chrX:129149363", "protein_effect": "V872G", "status": "unknown", "strand": "+", "transcript": "NM_021946", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.1922", "cds_effect": "1039C>T", "depth": "1103", "equivocal": "false", "functional_effect": "missense", "gene": "ERRFI1", "percent_reads": "19.22", "position": "chr1:8073620", "protein_effect": "P347S", "status": "unknown", "strand": "_", "transcript": "NM_018948", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.3954", "cds_effect": "3989C>T", "depth": "956", "equivocal": "false", "functional_effect": "missense", "gene": "TSC2", "percent_reads": "39.54", "position": "chr16:2133801", "protein_effect": "T1330M", "status": "unknown", "strand": "+", "transcript": "NM_000548", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.3222", "cds_effect": "1719C>G", "depth": "841", "equivocal": "false", "functional_effect": "missense", "gene": "PRDM1", "percent_reads": "32.22", "position": "chr6:106553754", "protein_effect": "I573M", "status": "unknown", "strand": "+", "transcript": "NM_001198", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.41", "cds_effect": "304T>A", "depth": "1083", "equivocal": "false", "functional_effect": "missense", "gene": "WHSC1", "percent_reads": "41.0", "position": "chr4:1902685", "protein_effect": "S102T", "status": "unknown", "strand": "+", "transcript": "NM_133335", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.6355", "cds_effect": "806C>A", "depth": "760", "equivocal": "false", "functional_effect": "missense", "gene": "KDM5A", "percent_reads": "63.55", "position": "chr12:464388", "protein_effect": "T269N", "status": "unknown", "strand": "_", "transcript": "NM_001042603", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.2037", "cds_effect": "811G>T", "depth": "545", "equivocal": "false", "functional_effect": "missense", "gene": "SDHB", "percent_reads": "20.37", "position": "chr1:17345408", "protein_effect": "A271S", "status": "unknown", "strand": "_", "transcript": "NM_003000", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.3541", "cds_effect": "2185_2186insTGGGC", "depth": "593", "equivocal": "false", "functional_effect": "frameshift", "gene": "ARID1A", "percent_reads": "35.41", "position": "chr1:27087898", "protein_effect": "P729fs*15", "status": "likely", "strand": "+", "transcript": "NM_006015", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.6484", "cds_effect": "22G>T", "depth": "805", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3C2G", "percent_reads": "64.84", "position": "chr12:18435037", "protein_effect": "D8Y", "status": "unknown", "strand": "+", "transcript": "NM_004570", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"allele_fraction": "0.6459", "cds_effect": "1765C>T", "depth": "627", "equivocal": "false", "functional_effect": "missense", "gene": "ABL1", "percent_reads": "64.59", "position": "chr9:133759442", "protein_effect": "R589C", "status": "known", "strand": "+", "transcript": "NM_005157", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "8", "equivocal": "true", "gene": "ZNF217", "number_of_exons": "4 of 4", "position": "chr20:52188273_52199365", "ratio": "1.3", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "AURKA", "number_of_exons": "8 of 8", "position": "chr20:54945213_54963296", "ratio": "1.28", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "12", "equivocal": "true", "gene": "RAD21", "number_of_exons": "13 of 13", "position": "chr8:117859738_117878968", "ratio": "1.59", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "12", "equivocal": "true", "gene": "MYC", "number_of_exons": "5 of 5", "position": "chr8:128748789_128753204", "ratio": "1.54", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "BCL2L1", "number_of_exons": "4 of 4", "position": "chr20:30253751_30310021", "ratio": "1.33", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "9", "equivocal": "true", "gene": "ERBB3", "number_of_exons": "28 of 28", "position": "chr12:56474060_56495839", "ratio": "1.34", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "12", "equivocal": "true", "gene": "LYN", "number_of_exons": "12 of 12", "position": "chr8:56854418_56922669", "ratio": "1.49", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "SRC", "number_of_exons": "11 of 11", "position": "chr20:36012556_36031782", "ratio": "1.34", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "ASXL1", "number_of_exons": "13 of 13", "position": "chr20:30946542_31025141", "ratio": "1.36", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "ARFRP1", "number_of_exons": "6 of 6", "position": "chr20:62331794_62338459", "ratio": "1.35", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "8", "equivocal": "true", "gene": "GNAS", "number_of_exons": "15 of 15", "position": "chr20:57415161_57485884", "ratio": "1.34", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}, {"copy_number": "12", "equivocal": "true", "gene": "NBN", "number_of_exons": "16 of 16", "position": "chr8:90947760_90996835", "ratio": "1.56", "status": "ambiguous", "type": "amplification", "dna_evidence": {"sample": "SQ_US1517083.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "4.83", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}